ateganosine + Cadonilimab
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Resectable Hepatocellular Carcinoma
Conditions
Resectable Hepatocellular Carcinoma
Trial Timeline
May 1, 2026 โ May 1, 2031
NCT ID
NCT07446257About ateganosine + Cadonilimab
ateganosine + Cadonilimab is a phase 1 stage product being developed by MAIA Biotechnology for Resectable Hepatocellular Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07446257. Target conditions include Resectable Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07446257 | Phase 1 | Recruiting |
Competing Products
20 competing products in Resectable Hepatocellular Carcinoma